Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 17/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 16/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20555587 | 0.82 | SIGMAR1 (0.53) | SIGMAR1OPRM1KCNH2 | |
| SCHEMBL20504475 | 0.82 | SIGMAR1 (0.59) | SIGMAR1OPRM1KCNH2 | |
| SCHEMBL17324891 | 0.81 | OPRM1 (0.47) | SIGMAR1OPRM1KCNH2 | |
| SCHEMBL20555663 | 0.81 | OPRM1 (0.47) | SIGMAR1OPRM1KCNH2 | |
| SCHEMBL22288679 | 0.80 | SIGMAR1 (0.49) | SIGMAR1OPRM1KCNH2 | |
| SCHEMBL17318996 | 0.79 | SIGMAR1 (0.65) | SIGMAR1OPRM1KCNH2 | |
| SCHEMBL18766532 | 0.78 | SIGMAR1 (0.55) | SIGMAR1OPRM1KCNH2 | |
| SCHEMBL17317227 | 0.78 | SIGMAR1 (0.45) | SIGMAR1OPRM1KCNH2 | |
| SCHEMBL13363110 | 0.77 | — | — | |
| SCHEMBL17317160 | 0.76 | SIGMAR1 (0.43) | SIGMAR1OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927128-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS. S.A. (ES) | 2021-02-23 | — | — | US | disclosed |
| US-20180327422-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2018-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327422-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | OPRD1, OPRM1, OPRK1 | SIGMAR1 4/4885OPRM1 2/4885KCNH2 2970/4885 |
| US-10927128-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | OPRD1, OPRM1, OPRK1 | SIGMAR1 4/4885OPRM1 2/4885KCNH2 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.